GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Landos Biopharma Inc (NAS:LABP) » Definitions » PB Ratio

Landos Biopharma (Landos Biopharma) PB Ratio : 2.19 (As of May. 02, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Landos Biopharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-05-02), Landos Biopharma's share price is $22.2931. Landos Biopharma's Book Value per Share for the quarter that ended in Dec. 2023 was $10.20. Hence, Landos Biopharma's PB Ratio of today is 2.19.

The historical rank and industry rank for Landos Biopharma's PB Ratio or its related term are showing as below:

LABP' s PB Ratio Range Over the Past 10 Years
Min: 0.16   Med: 0.42   Max: 6.39
Current: 2.19

During the past 6 years, Landos Biopharma's highest PB Ratio was 6.39. The lowest was 0.16. And the median was 0.42.

LABP's PB Ratio is ranked better than
54.12% of 1310 companies
in the Biotechnology industry
Industry Median: 2.435 vs LABP: 2.19

During the past 12 months, Landos Biopharma's average Book Value Per Share Growth Rate was 4.90% per year.

During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of Landos Biopharma was 256.30% per year. The lowest was 256.30% per year. And the median was 256.30% per year.

Back to Basics: PB Ratio


Landos Biopharma PB Ratio Historical Data

The historical data trend for Landos Biopharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Landos Biopharma PB Ratio Chart

Landos Biopharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PB Ratio
Get a 7-Day Free Trial - - 2.53 0.51 0.36

Landos Biopharma Quarterly Data
Dec18 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.51 0.20 0.30 0.32 0.36

Competitive Comparison of Landos Biopharma's PB Ratio

For the Biotechnology subindustry, Landos Biopharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Landos Biopharma's PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Landos Biopharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Landos Biopharma's PB Ratio falls into.



Landos Biopharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Landos Biopharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2023)
=22.2931/10.2
=2.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Landos Biopharma  (NAS:LABP) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Landos Biopharma PB Ratio Related Terms

Thank you for viewing the detailed overview of Landos Biopharma's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Landos Biopharma (Landos Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
P.O. Box 11239, Blacksburg, VA, USA, 24060
Landos Biopharma Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral therapeutics for patients with autoimmune diseases. It has several active development programs, each discovered internally, targeting novel pathways at the interface of immunity and metabolism. It operates in one reportable segment of operations and manages.
Executives
Alka Batycky director C/O LANDOS BIOPHARMA, INC., P.O. BOX 11239, BLACKSBURG VA 24062
Perceptive Xontogeny Venture Fund Ii, Lp 10 percent owner 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Roderick Wong 10 percent owner C/O RTW INVESTMENTS, LP, 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014
Fabio Cataldi officer: Chief Medical Officer C/O LANDOS BIOPHARMA, INC., PO BOX 11239, BLACKSBURG VA 24062
Gregory Oakes director, officer: Chief Executive Officer 760 PARKSIDE AVENUE, SUITE 304, BROOKLYN NY 11226
Patrick Truesdell officer: Vice President and Controller C/O LANDOS BIOPHARMA, INC., 1800 KRAFT DRIVE, SUITE 216, BLACKBURG VA 24060
Roger Adsett director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Josep Bassaganya-riera director, 10 percent owner, officer: Chairman, President and CEO 1800 KRAFT DRIVE, SUITE 100, BLACKSBURG VA 24060
Patricia L Bitar officer: Interim CFO C/O TRACON PHARMACEUTICALS, INC., 8910 UNIVERSITY CENTER LANE, STE 700, SAN DIEGO CA 92122
Perceptive Xontogeny Venture Fund, Lp director C/O PERCEPTIVE ADVISORS, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Xontogeny, Llc director 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Fred Callori director 100 HIGH STREET, 28TH FLOOR, BOSTON MA 02110
Joseph Edelman director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Perceptive Life Sciences Master Fund Ltd director C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003